HuMax-CD4: Phase I/II

In a 35-patient placebo controlled dose-escalating Phase I/II trial, HuMax-CD4 was well tolerated, with no evidence of depletion of CD4 T cells. At the 4 highest doses (0.5 mg/kg, 1 mg/kg, 2 mg/kg and...